Deferasirox Analytical Profiling through Analytical Method Development and Analytical Method Validation

Authors:

Abstract
Deferasirox, a regular oral iron chelator used to treat transfusion-related iron overload among people with chronic anaemias like beta thalassaemia. The drug's tridentate ligand structure helps it to bind ferric iron (Fe³⁺) with notable selectivity, making a stable 2:1 complex. It is not yet listed in official pharmacopoeias while being clinically significant. In this work, we define a validated analytical technique that uses high performance liquid chromatography (HPLC) with UV detection to predict deferasirox plasma concentrations. With a 10-minute run time and 248 nm monitoring chromatographic separation happened on C18 reverse phase column, offering a dependable and recurring method for measurement. The developed RP-HPLC method was found to be robust, rapid, and reliable for the analysis of Deferasirox with a retention time of 2.2 min. The method utilized green/eco-friendly solvent conditions with reduced chemical consumption, making it suitable for routine pharmaceutical analysis.